Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Browman

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Experimental Hematology|November 1, 1992
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup studyA Raza, S Gezer, J Anderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemiaH D Preisler, A Raza, R Larson, et al.
British Journal of Haematology|March 1, 1984
Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemiaH D Preisler, N Azarnia, A Raza, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1984
Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the diseaseH D Preisler, J Epstein, A Raza, et al.
British Journal of Haematology|August 1, 1986
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurementsH D Preisler, R Priore, N Azarnia, et al.
British Journal of Haematology|October 1, 1992
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup studyR A Larson, R S Day, N Azarnia, et al.
American Journal of Hematology|June 1, 1985
Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup studyJ Goldberg, H Grunwald, W R Vogler, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
Blood|January 1, 1985
Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemiaP B Neame, P Soamboonsrup, G Browman, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Experimental Hematology|November 1, 1992
Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup studyA Raza, S Gezer, J Anderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemiaH D Preisler, A Raza, R Larson, et al.
British Journal of Haematology|March 1, 1984
Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemiaH D Preisler, N Azarnia, A Raza, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1984
Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the diseaseH D Preisler, J Epstein, A Raza, et al.
British Journal of Haematology|August 1, 1986
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurementsH D Preisler, R Priore, N Azarnia, et al.
British Journal of Haematology|October 1, 1992
The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup studyR A Larson, R S Day, N Azarnia, et al.
American Journal of Hematology|June 1, 1985
Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup studyJ Goldberg, H Grunwald, W R Vogler, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
Blood|January 1, 1985
Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemiaP B Neame, P Soamboonsrup, G Browman, et al.
Pageof 6